The Max Delbrück Center in Berlin, one of Ascenion’s partner institutes, has entered into an exclusive intellectual property licensing agreement with Circular Genomics, a US-based molecular diagnostics company focused on circular RNA-based assays for neurological and psychiatric disorders. 

OMEICOS Therapeutics announce the successful conclusion of its multicentre, open-label Phase IIa PMD-OPTION Study evaluating its lead programme OMT-28 in patients with Primary Mitochondrial Disease (PMD).

Nearly 30 colleagues from technology transfer took part in Ascenion’s two-day workshop to learn about current developments and engage in intensive discussions.

Citrapeutics from the Helmholtz Centre for Infection Research (HZI) in Brunswick and RNA Healer from Hannover Medical School (MHH) receive a total of almost EUR 2.5 million in funding from IBT Lower Saxony to finance their innovations in biomedicine.

Ascenion’s new portfolio company Kernevo has set itself the goal of improving urine diagnostics. The challenge: cells in urine can only be kept intact for a very limited time. Kernevo’s solution: a patented technology stabilizes the samples, allowing them to remain analysable for much longer.

Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumours, announced the successful closing of an equity financing round. The funds will enable the company´s lead programme CTC127 to progress into a first-in-human Phase I clinical trial.

The award honors the iGUARD team for successfully translating research into medical innovation. Their platform enables the rapid creation of inhalable RNAi therapeutics against viral lung diseases. The transfer is being supported by Ascenion.

The acquisition of Berlin-based medtech company PhantomX by IBA expands global access to high-precision imaging and AI validation solutions. Ascenion and the techtransfer of Charité supported PhantomX throughout its start-up journey.

The figures show that we are on the right track together. Start-ups and new products are reaching the market. AI is driving innovation – and the most exciting phase is just beginning ...

Do you have an early-stage project in the life sciences and are looking for funding to kickstart it? Join Ascenion’s annual Information Webinar to learn all about the GO-Bio initial funding program by the German Federal Ministry of Research, Technology and Space.

BioVaria 2026 will take place on 27/28 April at the Sofitel Munich. Technology transfer partners from several European countries will present around 70 commercially attractive projects. Application deadline for Startup Pitch & Partner is 15 February.

Biophelion is Ascenion’s latest spin-off from its partner institute Leibniz-HKI and RWTH Aachen University. The start-up aims to accelerate the transition to a circular economy in the chemical industry with the help of a yeast-like fungus.

Ascenion’s portfolio company APTA Therapeutics has acquired the rights to Berlin Cures' rovunaptabin drug. After top line results from its Phase II trial failed to demonstrate the efficacy of the DNA aptamer, a new study at Erlangen University Hospital is now showing positive results.

Ascenion’s partner institute Charité – Universitätsmedizin Berlin and NeoPredics AG have entered into a licence agreement for the use of the innovative PreFree technology. The main goal is the early prediction of the risk prediction of pre-eclampsia.

The Hamburg-based start-up TimeTeller is delighted to announce a strategic investment from capacura GmbH. The company is convinced that TimeTeller’s technology has the potential to fundamentally change medical care.

Prague, Czech Republic

Ankara, Turkey

Cologne, Germany